Cost-effectiveness thresholds: pros and cons

被引:512
作者
Bertram, Melanie Y. [1 ]
Lauer, Jeremy A. [1 ]
De Joncheere, Kees [1 ]
Edejer, Tessa [1 ]
Hutubessy, Raymond [1 ]
Kieny, Marie-Paule [1 ]
Hill, Suzanne R. [1 ]
机构
[1] WHO, Ave Appia 20, CH-1211 Geneva 27, Switzerland
关键词
DECISION-ANALYSIS; HEPATITIS-C; HEALTH; INTERVENTIONS; REIMBURSEMENT; SOFOSBUVIR; AUSTRALIA; COUNTRIES; MIDDLE;
D O I
10.2471/BLT.15.164418
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Cost effectiveness analysis is used to compare the costs and outcomes of alternative policy options. Each resulting cost-effectiveness ratio represents the magnitude of additional health gained per additional unit of resources spent. Cost-effectiveness thresholds allow cost effectiveness ratios that represent good or very good value for money to be identified. In 2001, the World Health Organization's Commission on Macroeconomics in Health suggested,cost effectiveness thresholds based on multiples of a country's per-capita gross domestic product (GDP). In some contexts, in choosing which health interventions to fund and which not to fund, these thresholds have been used as decision-rules. However, experience with the use of such GDP-based thresholds in decision-making processes at country level shows them to lack country specificity and this in addition to uncertainty in the modelled cost effectiveness ratios - can lead to the wrong decision on how to spend health-care resources. Cost effectiveness information should be used alongside other considerations - e.g. budget impact and feasibility considerations in a transparent decision-making process, rather than in isolation based on a single threshold value. Although cost effectiveness ratios are undoubtedly informative in assessing value for money, countries should be encouraged to develop a context-specific process for decision-making that is supported by legislation, has stakeholder buy-in, for example the involvement of civil society organizations and patient groups, and is transparent, consistent and fair.
引用
收藏
页码:925 / 930
页数:6
相关论文
共 34 条
  • [1] Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment
    Angelis, Aris
    Kanavos, Panos
    [J]. PHARMACOECONOMICS, 2016, 34 (05) : 435 - 446
  • [2] [Anonymous], 2001, MACR HLTH INV HLTH E
  • [3] [Anonymous], 2012, RANK VACC PRIOR FRAM
  • [4] Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States
    Chhatwal, Jagpreet
    Kanwal, Fasiha
    Roberts, Mark S.
    Dunn, Michael A.
    [J]. ANNALS OF INTERNAL MEDICINE, 2015, 162 (06) : 397 - U114
  • [5] Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
    Claxton, Karl
    Martin, Steve
    Soares, Marta
    Rice, Nigel
    Spackman, Eldon
    Hinde, Sebastian
    Devlin, Nancy
    Smith, Peter C.
    Sculpher, Mark
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2015, 19 (14) : 1 - +
  • [6] CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?
    Claxton, Karl
    Sculpher, Mark
    Palmer, Stephen
    Culyer, Anthony J.
    [J]. HEALTH ECONOMICS, 2015, 24 (01) : 1 - 7
  • [7] Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries
    Creswell, Jacob
    Codlin, Andrew J.
    Andre, Emmanuel
    Micek, Mark A.
    Bedru, Ahmed
    Carter, E. Jane
    Yadav, Rajendra-Prasad
    Mosneaga, Andrei
    Rai, Bishwa
    Banu, Sayera
    Brouwer, Miranda
    Blok, Lucie
    Sahu, Suvanand
    Ditiu, Lucica
    [J]. BMC INFECTIOUS DISEASES, 2014, 14
  • [8] Economic foundations of cost-effectiveness analysis
    Garber, AM
    Phelps, CE
    [J]. JOURNAL OF HEALTH ECONOMICS, 1997, 16 (01) : 1 - 31
  • [9] Cost effectiveness analysis and the consistency of decision making - Evidence from pharmaceutical reimbursement in Australia (1991 to 1996)
    George, B
    Harris, A
    Mitchell, A
    [J]. PHARMACOECONOMICS, 2001, 19 (11) : 1103 - 1109
  • [10] GRADE guidelines: 7. Rating the quality of evidence-inconsistency
    Guyatt, Gordon H.
    Oxman, Andrew D.
    Kunz, Regina
    Woodcock, James
    Brozek, Jan
    Helfand, Mark
    Alonso-Coello, Pablo
    Glasziou, Paul
    Jaeschke, Roman
    Akl, Elie A.
    Norris, Susan
    Vist, Gunn
    Dahm, Philipp
    Shukla, Vijay K.
    Higgins, Julian
    Falck-Ytter, Yngve
    Schuenemann, Holger J.
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2011, 64 (12) : 1294 - 1302